Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer.

Reviews in urology 02/2006; 8(4):190-7.
Source: PubMed


Bladder cancer is a common malignancy in the United States. Although urine cytology is a useful adjunct in both diagnosis and follow-up and is highly sensitive for detecting high-grade tumors, it is limited by decreased sensitivity in detecting low-grade tumors, which constitute the majority of new diagnoses. Additional screening tests with high sensitivity and specificity for urothelial tumors of all grades are indicated to help improve the diagnostic ability of urine cytology as well as to reduce the need for frequent cystoscopies, especially in those with low-risk disease. Several assays have been developed, with the ImmunoCyt/uCyt+ test (DiagnoCure, Inc., Québec, Canada) being especially promising. Recent studies on the applicability and efficacy of ImmunoCyt/uCyt+ testing are reviewed, as are its sensitivity, specificity, and predictive value in the follow-up and screening of urothelial malignancies.

30 Reads
  • Source
    • "The ImmunoCyt/uCyt+ assay (Scimedx Corp, Denville, NJ, USA) is designed to augment cytology through the detection of cellular biomarkers on cytology slides using a cocktail of fluorescent monoclonal antibodies [36, 37]. The antigens targeted in the test are a high molecular weight form of carcinoembryonic antigen and two bladder tumor cell-associated mucins. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bladder cancer is one of the most prevalent cancers worldwide, but the treatment and management of this disease can be very successful if the disease is detected early. The development of molecular assays that could diagnose bladder cancer accurately, and at an early stage, would be a significant advance. Ideally, such molecular assays would be applicable to non-invasively obtained body fluids, and be designed not only for diagnosis but also for monitoring disease recurrence and response to treatment. In this article, we assess the performance of current diagnostic assays for bladder cancer and discuss some of the emerging biomarkers that could be developed to augment current bladder cancer detection strategies.
    Molecular Diagnosis & Therapy 03/2013; DOI:10.1007/s40291-013-0023-x · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hematuria is a common presenting symptom of urothelial malignancy. Although conventional urine analysis is very sensitive in detecting the presence of hematuria, it is not specific in detecting bladder cancer or other urinary-tract cancers. The noninvasive urinary tests NMP22 and UroVysion have been approved by the U.S. Food and Drug Administration for bladder cancer screening. These tests have better sensitivity than cytology for detecting bladder cancer in patients who present with hematuria. The positive predictive values of both tests increase in individuals with hematuria who have risk factors for bladder cancer. Evaluating hematuria with sensitive markers, such as NMP22 and UroVysion, in high-risk populations offers an opportunity to develop effective strategies for bladder cancer screening.
    World Journal of Urology 03/2008; 26(1):25-30. DOI:10.1007/s00345-007-0229-9 · 2.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Advances in understanding cancer at the molecular level have identified numerous alterations associated with cancer development and progression. The efforts in evaluating these putative biomarkers in clinical studies of patients with cancer are increasing in order to improve the clinical management of the disease. However, despite numerous attempts, the results of such biomarker studies are frequently inconsistent and sometimes even contradictory. Aim of this work is to discuss some of the recognized problems which have impeded our understanding of the role of new markers and prevented the introduction of these markers into patient management. These Problems include standardization issues, selection of patient cohorts and endpoints and statistical considerations. In order to improve and standardize marker development a stepwise procedure in four phases, analogous to clinical trials is proposed. Furthermore, a common terminology, considerations on the population to study as well as general recommendations for planning and conducting the evaluation of markers will be presented. The implementation of this discussion may foster the integration of new tools and strategies screening, diagnosis and surveillance of patients with bladder cancer.
    World Journal of Urology 03/2008; 26(1):5-11. DOI:10.1007/s00345-008-0240-9 · 2.67 Impact Factor
Show more


30 Reads
Available from